← Back to Search

Metabolic Inhibitor

CPI-613 + Hydroxychloroquine for Clear Cell Sarcoma

Phase 1 & 2
Waitlist Available
Research Sponsored by Rafael Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a combination of two drugs, hydroxychloroquine and devimistat, in patients whose Clear Cell Sarcoma of the Soft Tissue has returned or did not respond to previous treatments. Hydroxychloroquine helps make cancer cells more sensitive, while devimistat cuts off their energy supply. The goal is to find the best dose and see how well this combination works.

Eligible Conditions
  • Clear Cell Sarcoma
  • Clear Cell Sarcoma of Soft Tissue

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
MTD (Phase I)
ORR (Overall Response rate): CR +PR (Phase II)
Toxicity (Phase I)
Secondary study objectives
DOR (Duration of Response)
OS (Overall Survival)
PFS (Progression Free Survival)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CPI-613 + HydroxychloroquineExperimental Treatment1 Intervention
dosing regimen was 600mg hydroxychloroquine PO followed 2 hours later by 2,000 mg/m2 of CPI-613 by central IV infusion over 2 hours followed by 600 mg hydroxychloroquine PO 12 hours following the initial dose daily on days 1 through 5 of every 28 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CPI-613 + Hydroxychloroquine
2021
Completed Phase 2
~20

Find a Location

Who is running the clinical trial?

Rafael Pharmaceuticals Inc.Lead Sponsor
8 Previous Clinical Trials
780 Total Patients Enrolled
Cornerstone PharmaceuticalsLead Sponsor
14 Previous Clinical Trials
828 Total Patients Enrolled
~4 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top